Atherogenic L5 LDL Induces Cardiomyocyte Apoptosis And

Total Page:16

File Type:pdf, Size:1020Kb

Atherogenic L5 LDL Induces Cardiomyocyte Apoptosis And Ma et al. Lipids in Health and Disease (2020) 19:189 https://doi.org/10.1186/s12944-020-01368-7 RESEARCH Open Access Atherogenic L5 LDL induces cardiomyocyte apoptosis and inhibits KATP channels through CaMKII activation Yanzhuo Ma1,2, Nancy Cheng2, Junping Sun2, Jonathan Xuhai Lu3,4, Shahrzad Abbasi5, Geru Wu2, An-Sheng Lee6,7, Tatsuya Sawamura8,9, Jie Cheng2, Chu-Huang Chen3,8* and Yutao Xi1,10* Abstract Background: Cardiac Ca2+/calmodulin-dependent protein kinase II (CaMKII) activation plays a critical role in cardiomyocyte (CM) apoptosis and arrhythmia. Functional ATP-sensitive potassium (KATP) channels are essential for cardiac protection during ischemia. In cultured CMs, L5 low-density lipoprotein (LDL) induces apoptosis and QTc prolongation. L5 is a highly electronegative and atherogenic aberrant form of LDL, and its levels are significantly higher in patients with cardiovascular-related diseases. Here, the role of L5 in cardiac injury was studied by evaluating the effects of L5 on CaMKII activity and KATP channel physiology in CMs. Methods: Cultured neonatal rat CMs (NRCMs) were treated with a moderate concentration (ie, 7.5 μg/mL) of L5 or L1 (the least electronegative LDL subfraction). NRCMs were examined for apoptosis and viability, CaMKII activity, phox and the expression of phosphorylated CaMKIIδ and NOX2/gp91 . The function of KATP and action potentials (APs) was analyzed by using the patch-clamp technique. Results: In NRCMs, L5 but not L1 significantly induced cell apoptosis and reduced cell viability. Furthermore, L5 decreased Kir6.2 expression by more than 50%. Patch-clamp analysis showed that L5 reduced the KATP current (IKATP) density induced by pinacidil, a KATP opener. The partial recovery of the inward potassium current during pinacidil washout was susceptible to subsequent inhibition by the IKATP blocker glibenclamide. Suppression of IKATP by L5 significantly prolonged the AP duration. L5 also significantly increased the activity of CaMKII, the phosphorylation of CaMKIIδ, and the expression of NOX2/gp91phox. L5-induced apoptosis was prevented by the addition of the CaMKII inhibitor KN93 and the reactive oxygen species scavenger Mn (III)TBAP. Conclusions: L5 but not L1 induces CM damage through the activation of the CaMKII pathway and increases arrhythmogenicity in CMs by modulating the AP duration. These results help to explain the harmful effects of L5 in cardiovascular-related disease. Keywords: Action potential, ATP-sensitive potassium, Ca2+/calmodulin-dependent protein kinase II, Cardiomyocytes, Electronegative low-density lipoprotein * Correspondence: [email protected]; [email protected] 3Vascular and Medicinal Research, Texas Heart Institute, 6770 Bertner Avenue, Houston, TX 77030, USA 1Department of Cardiology, Bethune International Peace Hospital, 398 Zhongshan Xilu, Shijiazhuang 050082, Hebei, China Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Ma et al. Lipids in Health and Disease (2020) 19:189 Page 2 of 10 Background multistep sodium chloride gradient, as previously de- Low-density lipoprotein (LDL) can be resolved into five scribed [17]. charge-defined subfractions, L1 to L5. L1 is the least negatively charged and most abundant subfraction of Isolation of neonatal rat CMs (NRCMs) circulating LDL and represents the healthy and harmless NRCMs were isolated from neonatal Sprague Dawley LDL class [1, 2]. L5 is the most negatively charged sub- rats [18]. Experiments were conducted according to The fraction of circulating LDL and has been shown to in- Code of Ethics of the World Medical Association (Dec- duce cell apoptosis [3, 4]. Although L5 is nearly laration of Helsinki), and the animal procedures were undetectable in healthy individuals, its concentrations approved by the Institutional Animal Care and Use are significantly higher in patients with cardiovascular- Committee at the Texas Heart Institute (Houston, related diseases. Studies have indicated that L5 increases Texas, USA, protocol number #2011–18). Phenobarbital the incidence of thrombosis that contributes to ST- (10 mg/kg, administered intraperitoneally, Sigma-Aldrich elevation myocardial infarction (STEMI) [5, 6] and that Corp., St. Louis, MO, USA) was used to anesthetize the patients with STEMI have an increased risk of fatal neonatal rats, and the left ventricle was quickly excised arrhythmia [7]. In addition, L5 has been considered a and rinsed three times with ice-cold Dulbecco’s novel factor for predicting coronary vascular disease [8] phosphate-buffered saline (PBS; Invitrogen, Carlsbad, and stroke [9], and its concentrations are increased in CA, USA). The ventricles were minced by using micro- individuals with cardiovascular risk factors. In cultured dissection in a dry petri dish and then by enzymatic di- cardiomyocytes (CMs), L5 has been reported to induce gestion with type II collagenase (Worthington cell apoptosis via cytokines released from vascular endo- Biochemical Co, Lakewood, NJ, USA) and procaine thelial cells [10]. Recently, it has been demonstrated that (Sigma-Aldrich Corp). After digestion, the cells were L5 causes prolongation of the corrected QT interval harvested and suspended in Dulbecco’s Modified Eagle’s (QTc) by mediating the current of L-type calcium and medium (DMEM, Gibco, Carlsbad, CA, USA) with 10% transient activated potassium channels [11]. Functional fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, ATP-sensitive potassium channels (KATP) are essential USA), penicillin and streptomycin (100 U/mL, Invitro- for ischemic preconditioning, post-ischemia cardiac pro- gen, Grand Island, NY, USA), and 2 mM glutamate tection, and regulation of atrial and ventricular rhythm (Invitrogen). Next, the cells were placed on 100-mm cul- during cardiac ischemia [12, 13]. However, the effect of ture dishes, and the culture dishes were placed in a L5 on KATP current (IKATP) has not been studied. 37 °C incubator with 5% CO2. After fibroblasts settled, Cardiac Ca2+/calmodulin-dependent protein kinase II the supernatants were collected and replated for the fol- (CaMKII) is an underlying mechanism of CM apoptosis lowing experiments. and arrhythmia [14, 15]. CaMKII oxidation serves as an intermediate of oxidative stress and correlates with in- Cell apoptosis assays creased apoptosis in cardiac cells [16]. In this study, the NRCMs were starved overnight by using serum-free cul- effects of L5 on the electrophysiologic properties of CMs ture medium and were subjected to incubation with L5 were examined, as well as whether L5 induces CM dam- or L1 for 24 h. Cell apoptosis was analyzed by using age through CaMKIIδ via the oxidation and phosphoryl- staining. Briefly, NRCMs (1.0 × 105 cells/mL) were ation of its regulatory domain. treated with different concentrations of L5 (0.075, 0.25, 0.75, 2.5, 7.5, 25, 75, or 250 μg/mL) overnight. Parafor- Methods maldehyde (5%) was used to fix the NRCMs. Then, the L5 preparation and ion-exchange purification cells were incubated with Triton X-100 (0.1%) for 5 min. Whole LDL was respectively collected from 10 pa- Next, the cells were stained with Hoechst (blue) for 15 tients with STEMI and metabolic syndrome, as de- min and were observed by using a fluorescence micro- scribed previously [1], with approval from the scope. For Annexin V-Alexa 488/ propidium iodide (PI) Institutional Review Board at the Texas Heart Insti- staining (Invitrogen), NRCMs (1.0 × 105 cells/mL) were tute (Houston, Texas, USA). Plasma samples were placed in a 12-well culture plate and were treated with equilibrated by performing dialysis in a column various concentrations of L5 (0.075, 0.25, 0.75, 2.5, 7.5, loaded with buffer A (20 mmol/L Tris HCl [pH 8.0], 25, 75, or 250 μg/mL) overnight. NRCMs were collected 0.5 mmol/L EDTA, and 1% penicillin-streptomycin). and rinsed with ice-cold PBS, followed by centrifugation Approximately 100 mg of LDL was injected onto a and resuspension with 100 μL annexin binding buffer. UnoQ12 anion-exchange column (Bio-Rad, Richmond, Next, 5 μL Annexin V mixed with 1 μL PI (100 μg/mL) CA) by using a GE AKTA fast-protein liquid chroma- was added to the binding buffer. The cells were placed tography system (GE Healthcare Life Sciences, Logan, in the darkroom at room temperature. Then, 400 μL Utah, USA). LDL subfractions were eluted by using a annexin binding buffer was added 15 min later, and cell Ma et al. Lipids in Health and Disease (2020) 19:189 Page 3 of 10 apoptosis was measured by using a BD Biosciences im- 10 HEPES, and 10 glucose (pH 7.35 adjusted with aging system. Cells staining positive for PI were ex- NaOH). Calcium current blocker, nifedipine (2 nM, cluded, and the ratio of Annexin V–positive cells to Sigma), Glibenclamide transient potassium current nuclei was quantified. blocker, and 4-aminopyridine (2 mmol/L, Sigma-Aldrich Apo-ONE Homogeneous Caspase-3/7 Assay (Pro- Corp) were added. A − 40 mV prepulse was used to de- mega, Madison, WI, USA) was used to examine cell activate sodium currents.
Recommended publications
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Un Novedoso Enfoque Para El Diseño De Fármacos Antimicrobianos Asistido Por Computadora
    TOMOCOMD-CARDD: Un Novedoso Enfoque para el Diseño de Fármacos Antimicrobianos Asistido por Computadora Autora: Yasnay Valdés Rodríguez. Tutores: Prof. Dr. Yovani Marrero Ponce. Prof. MSc. Ricardo Medina Marrero. 2005-2006 La ignorancia afirma o niega rotundamente; la ciencia duda… Voltaire (1694-1778) Quiero dedicar este trabajo a todas aquellas personas que me aprecian y desean lo mejor para mi, especialmente a mis padres. A mi padre Dedico este trabajo con mucho amor, por hacerme comprender que siempre se puede llegar mas lejos, y que no hay nada imposible, solamente hay que luchar... A mi madre Por su infinita bondad, por su sacrificio inigualable. A mis familiares Por todo su apoyo y ayuda que me han mostrado incondicionalmente. A mi hermano Por ser mi fuente de inspiración. A la humanidad “...porque si supiera que el mundo se acaba mañana, yo, hoy todavía, plantaría un árbol” Quiero agradecer a todas aquellas personas que me han ayudado a realizar este sueño: A mis padres por todo el sacrificio realizado, y aún parecerles poco, los amo mucho. A mi madre por estar siempre a mi lado en los buenos y malos momentos ayudándome a levantarme en cualquier recaída. A mi padre por guiarme en la vida y brindarme sus consejos siempre útiles, por darme fuerza y vitalidad. A mi mayor tesoro, mi hermano, que me alumbra de esperanza día a día. A mis tías y primos que me ayudaron mucho, aún estando lejos. A mi novio que me apoyo en todas mis decisiones y con paciencia supo ayudarme. A mis tutores y cotutores que siempre me dieron la mano; especialmente a Yovani por su paciencia, a quien debo gran parte de mi formación como profesional por sus exigencias.
    [Show full text]
  • Identification of a Series of Hair-Cell MET Channel Blockers That Protect Against Aminoglycoside-Induced Ototoxicity
    Identification of a series of hair-cell MET channel blockers that protect against aminoglycoside-induced ototoxicity Emma J. Kenyon, … , Corné J. Kros, Guy P. Richardson JCI Insight. 2021;6(7):e145704. https://doi.org/10.1172/jci.insight.145704. Research Article Neuroscience Therapeutics Graphical abstract Find the latest version: https://jci.me/145704/pdf RESEARCH ARTICLE Identification of a series of hair-cell MET channel blockers that protect against aminoglycoside-induced ototoxicity Emma J. Kenyon,1 Nerissa K. Kirkwood,1 Siân R. Kitcher,1 Richard J. Goodyear,1 Marco Derudas,2 Daire M. Cantillon,3 Sarah Baxendale,4 Antonio de la Vega de León,5 Virginia N. Mahieu,1 Richard T. Osgood,1 Charlotte Donald Wilson,1 James C. Bull,6 Simon J. Waddell,3 Tanya T. Whitfield,4 Simon E. Ward,7 Corné J. Kros,1 and Guy P. Richardson1 1Sussex Neuroscience and 2Sussex Drug Discovery Centre, School of Life Sciences, and 3Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom. 4Bateson Centre and Department of Biomedical Science, and 5Information School, University of Sheffield, Sheffield, United Kingdom. 6Department of Biosciences, College of Science, Swansea University, Swansea, United Kingdom. 7Medicines Discovery Institute, Cardiff University, Cardiff, United Kingdom. To identify small molecules that shield mammalian sensory hair cells from the ototoxic side effects of aminoglycoside antibiotics, 10,240 compounds were initially screened in zebrafish larvae, selecting for those that protected lateral-line hair cells against neomycin and gentamicin. When the 64 hits from this screen were retested in mouse cochlear cultures, 8 protected outer hair cells (OHCs) from gentamicin in vitro without causing hair-bundle damage.
    [Show full text]
  • Systematic Evidence Review from the Blood Pressure Expert Panel, 2013
    Managing Blood Pressure in Adults Systematic Evidence Review From the Blood Pressure Expert Panel, 2013 Contents Foreword ............................................................................................................................................ vi Blood Pressure Expert Panel ..............................................................................................................vii Section 1: Background and Description of the NHLBI Cardiovascular Risk Reduction Project ............ 1 A. Background .............................................................................................................................. 1 Section 2: Process and Methods Overview ......................................................................................... 3 A. Evidence-Based Approach ....................................................................................................... 3 i. Overview of the Evidence-Based Methodology ................................................................. 3 ii. System for Grading the Body of Evidence ......................................................................... 4 iii. Peer-Review Process ....................................................................................................... 5 B. Critical Question–Based Approach ........................................................................................... 5 i. How the Questions Were Selected ................................................................................... 5 ii. Rationale for the Questions
    [Show full text]
  • Identification of a Novel Series of Hair-Cell MET Channel Blockers That Protect Against Aminoglycoside-Induced Ototoxicity
    Identification of a novel series of hair-cell MET channel blockers that protect against aminoglycoside-induced ototoxicity Emma J. Kenyon, … , Corné J. Kros, Guy P. Richardson. JCI Insight. 2021. https://doi.org/10.1172/jci.insight.145704. Research In-Press Preview Neuroscience Therapeutics Graphical abstract Find the latest version: https://jci.me/145704/pdf Identification of a series of hair-cell MET channel blockers that protect against aminoglycoside-induced ototoxicity Emma J Kenyon1*, Nerissa K Kirkwood1*, Siân R Kitcher1*, Richard J Goodyear1, Marco Derudas2, Daire M Cantillon3, Sarah Baxendale4, Antonio de la Vega de León5 , Virginia N Mahieu1, Richard T Osgood1, Charlotte Donald Wilson1, James C Bull6, Simon J Waddell3, Tanya T Whitfield4, Simon E Ward7, Corné J Kros1 and Guy P Richardson1. 1Sussex Neuroscience, School of Life Sciences, University of Sussex, Brighton, BN1 9QG, UK 2Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Brighton, BN1 9QG, UK 3Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9PX, UK 4Bateson Centre and Department of Biomedical Science, University of Sheffield, Sheffield, S10 2TN, UK 5Information School, University of Sheffield, Regent Court, 211 Portobello, Sheffield. S1 4DP, UK 6Department of Biosciences, College of Science, Swansea University, Swansea, SA2 8PP, UK 7Medicines Discovery Institute, Cardiff University, Cardiff, CF10 3AT, UK *These authors contributed equally to the work and are listed in alphabetical order. Corresponding authors Prof. Guy P Richardson, School of Life Sciences, University of Sussex, Falmer, Brighton, BN1 9QG, UK. Phone 0044 1273 678717. Email: [email protected] Prof. Corné J Kros, School of Life Sciences, University of Sussex, Falmer, Brighton, BN1 9QG, UK.
    [Show full text]
  • ORC-13661 Protects Sensory Hair Cells from Aminoglycoside and Cisplatin Ototoxicity
    ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity Siân R. Kitcher, … , Guy P. Richardson, Corné J. Kros JCI Insight. 2019;4(15):e126764. https://doi.org/10.1172/jci.insight.126764. Research Article Neuroscience Therapeutics Aminoglycoside (AG) antibiotics are widely used to prevent life-threatening infections, and cisplatin is used in the treatment of various cancers, but both are ototoxic and result in loss of sensory hair cells from the inner ear. ORC-13661 is a new drug that was derived from PROTO-1, a compound first identified as protective in a large-scale screen utilizing hair cells in the lateral line organs of zebrafish larvae. Here, we demonstrate, in zebrafish larvae and in mouse cochlear cultures, that ORC-13661 provides robust protection of hair cells against both ototoxins, the AGs and cisplatin. ORC- 13661 also prevents both hearing loss in a dose-dependent manner in rats treated with amikacin and the loading of neomycin-Texas Red into lateral line hair cells. In addition, patch-clamp recordings in mouse cochlear cultures reveal that ORC-13661 is a high-affinity permeant blocker of the mechanoelectrical transducer (MET) channel in outer hair cells, suggesting that it may reduce the toxicity of AGs by directly competing for entry at the level of the MET channel and of cisplatin by a MET-dependent mechanism. ORC-13661 is therefore a promising and versatile protectant that reversibly blocks the hair cell MET channel and operates across multiple species and toxins. Find the latest version: https://jci.me/126764/pdf RESEARCH ARTICLE ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity Siân R.
    [Show full text]
  • Synergistic and Antagonistic Drug Interactions in the Treatment
    RESEARCH ARTICLE Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections Morgan A Wambaugh, Steven T Denham, Magali Ayala, Brianna Brammer, Miekan A Stonhill, Jessica CS Brown* Division of Microbiology and Immunology, Pathology Department, University of Utah School of Medicine, Salt Lake City, United States Abstract Invasive fungal infections cause 1.6 million deaths annually, primarily in immunocompromised individuals. Mortality rates are as high as 90% due to limited treatments. The azole class antifungal, fluconazole, is widely available and has multi-species activity but only inhibits growth instead of killing fungal cells, necessitating long treatments. To improve treatment, we used our novel high-throughput method, the overlap2 method (O2M) to identify drugs that interact with fluconazole, either increasing or decreasing efficacy. We identified 40 molecules that act synergistically (amplify activity) and 19 molecules that act antagonistically (decrease efficacy) when combined with fluconazole. We found that critical frontline beta-lactam antibiotics antagonize fluconazole activity. A promising fluconazole-synergizing anticholinergic drug, dicyclomine, increases fungal cell permeability and inhibits nutrient intake when combined with fluconazole. In vivo, this combination doubled the time-to-endpoint of mice with Cryptococcus neoformans meningitis. Thus, our ability to rapidly identify synergistic and antagonistic drug interactions can potentially alter the patient outcomes. *For correspondence: Introduction [email protected] Invasive fungal infections are an increasing problem worldwide, contributing to 1.6 million deaths annually (Almeida et al., 2019; Bongomin et al., 2017; Brown et al., 2012). These problematic Competing interests: The infections are difficult to treat for many reasons. Delayed diagnoses, the paucity and toxicity of anti- authors declare that no fungal drugs, and the already immunocompromised state of many patients result in mortality rates competing interests exist.
    [Show full text]
  • Potential Therapeutic Approaches for Modulating Expression and Accumulation of Defective Lamin a in Laminopathies and Age-Related Diseases
    J Mol Med (2012) 90:1361–1389 DOI 10.1007/s00109-012-0962-4 REVIEW Potential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseases Alex Zhavoronkov & Zeljka Smit-McBride & Kieran J. Guinan & Maria Litovchenko & Alexey Moskalev Received: 6 May 2012 /Revised: 8 September 2012 /Accepted: 25 September 2012 /Published online: 23 October 2012 # The Author(s) 2012. This article is published with open access at Springerlink.com Abstract Scientific understanding of the genetic compo- rise to lethal, early-onset diseases known as laminopathies. nents of aging has increased in recent years, with several Here, we analyze the literature and conduct computational genes being identified as playing roles in the aging process analyses of lamin A signaling and intracellular interactions and, potentially, longevity. In particular, genes encoding in order to examine potential mechanisms for altering or components of the nuclear lamina in eukaryotes have been slowing down aberrant Lamin A expression and/or for re- increasingly well characterized, owing in part to their clin- storing the ratio of normal to aberrant lamin A. The ultimate ical significance in age-related diseases. This review focuses goal of such studies is to ameliorate or combat laminopa- on one such gene, which encodes lamin A, a key component thies and related diseases of aging, and we provide a dis- of the nuclear lamina. Genetic variation in this gene can give cussion of current approaches in this review. A. Zhavoronkov (*) : M. Litovchenko Keywords Lamin A Progeria Laminopathies Bioinformatics and Medical Information Technology Laboratory, Age-related diseases .
    [Show full text]
  • Novel Modulation of Adenylyl Cyclase Type 2 Jason Michael Conley Purdue University
    Purdue University Purdue e-Pubs Open Access Dissertations Theses and Dissertations Fall 2013 Novel Modulation of Adenylyl Cyclase Type 2 Jason Michael Conley Purdue University Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations Part of the Medicinal-Pharmaceutical Chemistry Commons Recommended Citation Conley, Jason Michael, "Novel Modulation of Adenylyl Cyclase Type 2" (2013). Open Access Dissertations. 211. https://docs.lib.purdue.edu/open_access_dissertations/211 This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact [email protected] for additional information. Graduate School ETD Form 9 (Revised 12/07) PURDUE UNIVERSITY GRADUATE SCHOOL Thesis/Dissertation Acceptance This is to certify that the thesis/dissertation prepared By Jason Michael Conley Entitled NOVEL MODULATION OF ADENYLYL CYCLASE TYPE 2 Doctor of Philosophy For the degree of Is approved by the final examining committee: Val Watts Chair Gregory Hockerman Ryan Drenan Donald Ready To the best of my knowledge and as understood by the student in the Research Integrity and Copyright Disclaimer (Graduate School Form 20), this thesis/dissertation adheres to the provisions of Purdue University’s “Policy on Integrity in Research” and the use of copyrighted material. Approved by Major Professor(s): ____________________________________Val Watts ____________________________________ Approved by: Jean-Christophe Rochet 08/16/2013 Head of the Graduate Program Date i NOVEL MODULATION OF ADENYLYL CYCLASE TYPE 2 A Dissertation Submitted to the Faculty of Purdue University by Jason Michael Conley In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy December 2013 Purdue University West Lafayette, Indiana ii For my parents iii ACKNOWLEDGEMENTS I am very grateful for the mentorship of Dr.
    [Show full text]
  • Synergistic and Antagonistic Drug Interactions in the Treatment of Systemic Fungal Infections
    bioRxiv preprint doi: https://doi.org/10.1101/843540; this version posted November 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Synergistic and Antagonistic Drug Interactions in the Treatment of Systemic Fungal Infections Morgan A. Wambaugh, Steven T. Denham, Brianna Brammer, Miekan Stonhill, and Jessica C. S. Brown Division of Microbiology and Immunology, Pathology Department, University of Utah School of Medicine, Salt Lake City, UT 84132, USA [email protected]; [email protected] Keywords Cryptococcus neoformans, overlap2 method (O2M), synergy, antagonism, drug interactions, fluconazole, dicyclomine hydrochloride, berbamine hydrochloride, nafcillin sodium, Candida species Summary Invasive fungal infections cause 1.6 million deaths annually, primarily in immunocompromised individuals. Mortality rates are as high as 90% due to limited number of efficacious drugs and poor drug availability. The azole class antifungal, fluconazole, is widely available and has multi-species activity but only inhibits fungal cell growth instead of killing fungal cells, necessitating long treatments. To improve fluconazole treatments, we used our novel high-throughput method, the overlap2 method (O2M), to identify drugs that interact with fluconazole, either increasing or decreasing efficacy. Although serendipitous identification of these interactions is rare, O2M allows us to screen molecules five times faster than testing combinations individually and greatly enriches for interactors. We identified 40 molecules that act synergistically (amplify activity) and 19 molecules that act antagonistically (decrease efficacy) when combined with fluconazole. We found that critical frontline beta-lactam antibiotics antagonize fluconazole activity. A promising fluconazole-synergizing anticholinergic drug, dicyclomine, increases fungal cell permeability and inhibits nutrient intake when combined with fluconazole.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Pesticide
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Pesticide Chemical Dosage (+)-(1S,10R)-1,10-DIMETHYLBICYCLO(4.4.
    [Show full text]
  • Identificación “In Silico” Y Corroboración “In Vitro” De Nuevos Compuestos Con Actividad Analgésica
    Universidad Central “Martha Abreu” de Las Villas. Facultad de Química-Farmacia. Departamento de Farmacia. Trabajo de Diploma Identificación “in silico” y corroboración “in vitro” de nuevos compuestos con actividad analgésica. Autora: Oremia del Toro Cortés Tutores: Dr.: Yovany Marrero Ponce Dr. Gerardo Casañola Martín Msc. Arelys López Sacerio Asesor: Dr. Juan Alberto Castillo Garit Santa Clara. 2009. ________________________________________________________________________ La sabiduría es vida para quien la obtiene; ¡dichoso los que saben retenerla! Proverbio 3.18 ________________________________________________________________________ ________________________________________________________________________ Dedicatoria A mis padres por traerme al mundo y luego enseñarme a vivir, a mi tía por mostrarme el camino con su infinito amor y al resto de mi familia, especialmente a mis abuelos. A mi esposo por no faltar a su promesa de amarme en las buenas y en las malas y por brindarme su apoyo incondicional cada día de mi vida. ________________________________________________________________________ ________________________________________________________________________ Agradecimientos Es una satisfacción para mí expresar mis más sinceros agradecimientos a todas aquellas personas de una manera u otra me han ayudado a culminar exitosamente mis estudios y este trabajo. Quisiera agradecer especialmente a mi familia y a mi esposo por confiar en mí y por todo el apoyo y el amor que me han brindado durante todo el transcurso de mi carrera. A mis tutores Arelys y Gerardo por su apoyo, ánimo y dirección durante el desarrollo de este trabajo. Al Grupo de Diseño de Fármacos, especialmente a Juan Alberto por su atención y toda la ayuda que me ha brindado para el desarrollo de esta tesis. A mis compañeros de aula especialmente a Leyanis, Zuleidys Yunier y Yamilka por estar conmigo en los momentos buenos y malos durante estos cinco años de mi vida estudiantil.
    [Show full text]